BACKGROUND: Low grade inflammation is of pathogenic importance in the development of cardiovascular disease (CVD) and type 2 diabetes. The inflammation marker YKL-40 correlates with insulin resistance and is highly expressed in atherosclerotic plaques. We aimed to investigate whether YKL-40 could predict overall and cardiovascular (CV) mortality in a 50+ years population without known CVD. METHODS: A representative population sample of 639 individuals aged 50-89 years was recruited from general practices. Examination at baseline included echocardiography and blood and urine samples for CV risk factors and markers including lipids, high sensitive C-reactive protein (hsCRP), N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) and urinary albumin/creatinine-ratio (UACR). Median follow-up period was 5.0 (0.17-5.28) years. RESULTS: In subjects without diabetes and CVD at baseline, increasing YKL-40 levels independently predicted overall and CV mortality rate with hazard ratios of 1.58 (95% confidence interval (CI), 1.12-2.23, p=0.009) and 1.57 (95% CI, 1.00-2.46, p=0.049) after adjustment for age, sex, smoking, total cholesterol, hsCRP, NT-proBNP and UACR. In combined Kaplan-Meier analyses, baseline values of both YKL-40 and UACR above median significantly predicted increased cumulative overall and CV mortality rates in subjects without diabetes or CVD at baseline (30.6% vs. <or=8%, respectively 10.6%<or=3%, p<0.0001). CONCLUSIONS: YKL-40 seems to be an independent predictor of overall and CV mortality in an elderly part of the general population without diabetes and CVD. YKL-40 and UACR are both independent predictors, that seem to predict overall and CV mortality in a synergistic way. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
BACKGROUND: Low grade inflammation is of pathogenic importance in the development of cardiovascular disease (CVD) and type 2 diabetes. The inflammation marker YKL-40 correlates with insulin resistance and is highly expressed in atherosclerotic plaques. We aimed to investigate whether YKL-40 could predict overall and cardiovascular (CV) mortality in a 50+ years population without known CVD. METHODS: A representative population sample of 639 individuals aged 50-89 years was recruited from general practices. Examination at baseline included echocardiography and blood and urine samples for CV risk factors and markers including lipids, high sensitive C-reactive protein (hsCRP), N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) and urinary albumin/creatinine-ratio (UACR). Median follow-up period was 5.0 (0.17-5.28) years. RESULTS: In subjects without diabetes and CVD at baseline, increasing YKL-40 levels independently predicted overall and CV mortality rate with hazard ratios of 1.58 (95% confidence interval (CI), 1.12-2.23, p=0.009) and 1.57 (95% CI, 1.00-2.46, p=0.049) after adjustment for age, sex, smoking, total cholesterol, hsCRP, NT-proBNP and UACR. In combined Kaplan-Meier analyses, baseline values of both YKL-40 and UACR above median significantly predicted increased cumulative overall and CV mortality rates in subjects without diabetes or CVD at baseline (30.6% vs. <or=8%, respectively 10.6%<or=3%, p<0.0001). CONCLUSIONS:YKL-40 seems to be an independent predictor of overall and CV mortality in an elderly part of the general population without diabetes and CVD. YKL-40 and UACR are both independent predictors, that seem to predict overall and CV mortality in a synergistic way. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors: Naja Dam Mygind; Marina J Harutyunyan; Anders Bruun Mathiasen; Rasmus S Ripa; Jens Jacob Thune; Jens Peter Gøtze; Julia S Johansen; Jens Kastrup Journal: Inflamm Res Date: 2010-10-23 Impact factor: 4.575
Authors: Marialaura Bonaccio; Augusto Di Castelnuovo; George Pounis; Amalia De Curtis; Simona Costanzo; Mariarosaria Persichillo; Chiara Cerletti; Maria Benedetta Donati; Giovanni de Gaetano; Licia Iacoviello Journal: Haematologica Date: 2016-10-14 Impact factor: 9.941
Authors: Chun Geun Lee; Carla A Da Silva; Charles S Dela Cruz; Farida Ahangari; Bing Ma; Min-Jong Kang; Chuan-Hua He; Seyedtaghi Takyar; Jack A Elias Journal: Annu Rev Physiol Date: 2011 Impact factor: 19.318
Authors: Breno S Diniz; Charles F Reynolds; Meryl A Butters; Mary Amanda Dew; Josélia O A Firmo; Maria Fernanda Lima-Costa; Erico Castro-Costa Journal: Depress Anxiety Date: 2013-12-18 Impact factor: 6.505
Authors: Camilla Noelle Rathcke; Erik Kjøller; Niels Fogh-Andersen; Bo Zerahn; Henrik Vestergaard Journal: PLoS One Date: 2010-12-01 Impact factor: 3.240